Estimating the Prevalence of a True Oligometastatic Disease

Petr Szturz; Pierluigi Bonomo; Jan B Vermorken

doi:10.3390/cancers15010214

Estimating the Prevalence of a True Oligometastatic Disease

Cancers (Basel). 2022 Dec 30;15(1):214. doi: 10.3390/cancers15010214.

Authors

Petr Szturz^{1

2}, Pierluigi Bonomo³, Jan B Vermorken^{4

5}

Affiliations

¹ Medical Oncology, Department of Oncology, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland.
² Faculty of Biology and Medicine, University of Lausanne (UNIL), 1011 Lausanne, Switzerland.
³ Department of Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, 50134 Florence, Italy.
⁴ Department of Medical Oncology, Antwerp University Hospital, 2650 Edegem, Belgium.
⁵ Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Antwerp, Belgium.

Abstract

To delineate a patient group with few distant metastases that could possibly benefit from a curative therapeutic strategy employing a local approach, the term oligometastatic disease (OMD) was introduced into the clinical practice almost 30 years ago [...].

Publication types

Editorial

Grants and funding

This research received no external funding.